O	0	1	[
O	1	9	Survival
O	10	12	of
O	13	19	breast
O	20	26	cancer
O	27	35	patients
O	36	43	treated
O	44	48	with
B-intervention	49	59	inhibitors
I-intervention	60	62	of
I-intervention	63	66	the
I-intervention	67	76	aromatase
O	77	79	vs
B-control	80	89	tamoxifen
O	89	90	]
O	90	91	.

O	92	94	In
B-location	95	101	Mexico
O	102	105	the
O	106	112	breast
O	113	119	cancer
O	120	128	occupies
O	129	132	the
O	133	139	second
O	140	145	place
O	146	148	as
O	149	154	cause
O	155	157	of
O	158	163	death
O	164	166	by
O	167	178	oncological
O	179	186	illness
O	187	190	and
O	191	194	the
O	195	203	etiology
O	204	206	is
O	207	217	considered
O	218	232	multifactorial
O	232	233	.

O	234	237	The
O	238	246	systemic
O	247	256	treatment
O	257	259	of
O	260	264	this
O	265	271	cancer
O	272	274	is
O	275	286	necessarily
O	287	292	after
O	293	296	the
O	297	304	surgery
O	305	308	and
O	309	323	simultaneously
O	324	328	when
O	329	341	radiotherapy
O	342	344	is
O	345	349	used
O	349	350	;
O	351	360	therefore
O	361	364	the
O	365	371	recent
O	372	384	introduction
O	385	387	of
O	388	393	newly
O	394	397	non
O	398	404	toxics
O	405	408	and
O	409	418	efficient
O	419	432	antiestrogens
O	433	438	which
O	439	444	block
O	445	448	the
O	449	455	effect
O	456	458	of
O	459	468	estrogens
O	469	473	from
O	474	485	circulation
O	486	490	have
O	491	497	become
O	498	503	drugs
O	504	506	of
O	507	512	first
O	513	517	line
O	518	520	in
O	521	524	the
O	525	535	metastasis
O	536	543	illness
O	543	544	.

O	545	547	To
O	548	555	compare
O	556	559	the
O	560	568	clinical
O	569	578	evolution
O	579	582	and
O	583	586	the
O	587	595	survival
O	596	598	of
O	599	607	patients
O	608	612	with
O	613	620	locally
O	621	629	advanced
O	630	636	breast
O	637	643	cancer
O	644	647	and
O	648	658	metastasis
O	659	663	with
O	664	667	the
O	668	671	use
O	672	674	of
O	675	678	two
O	679	690	therapeutic
O	691	701	modalities
O	701	702	.

O	703	708	Under
O	709	717	informed
O	718	725	consent
B-total-participants	726	728	20
B-eligibility	729	737	patients
I-eligibility	738	742	with
I-eligibility	743	752	diagnosis
I-eligibility	753	755	of
I-eligibility	756	762	breast
I-eligibility	763	769	cancer
I-eligibility	770	773	and
I-eligibility	774	777	out
I-eligibility	778	780	of
I-eligibility	781	792	oncological
I-eligibility	793	804	therapeutic
I-eligibility	805	815	processing
O	816	820	were
O	821	829	included
O	829	830	.

O	831	839	Randomly
O	840	842	an
O	843	852	inhibitor
O	853	855	of
O	856	859	the
O	860	869	aromatase
O	870	871	(
O	871	882	anastrozole
O	882	883	,
O	884	885	1
O	886	888	mg
O	889	892	for
O	893	896	day
O	896	897	)
O	898	901	was
O	902	906	used
O	907	909	in
B-intervention-participants	910	912	10
O	913	921	patients
O	922	925	and
O	926	928	in
O	929	932	the
O	933	938	other
B-control-participants	939	941	10
O	942	950	patients
O	951	960	tamoxifen
O	961	962	(
O	962	964	20
O	965	967	mg
O	968	971	for
O	972	975	day
O	975	976	)
O	977	981	both
O	982	985	for
O	986	987	2
O	988	993	years
O	993	994	,
O	995	1002	subject
O	1003	1005	to
O	1006	1018	verification
O	1019	1021	of
O	1022	1030	positive
O	1031	1040	estrogens
O	1040	1041	-
O	1041	1053	progesterone
O	1054	1063	receptors
O	1063	1064	.

O	1065	1069	Half
O	1070	1072	of
O	1073	1076	the
O	1077	1085	patients
O	1086	1088	of
O	1089	1093	each
O	1094	1099	group
O	1100	1103	had
O	1104	1105	a
O	1106	1114	clinical
O	1115	1120	stage
O	1121	1124	III
O	1124	1125	.

O	1126	1129	The
O	1130	1134	most
O	1135	1143	frequent
O	1144	1156	histological
O	1157	1166	diagnosis
O	1167	1170	was
O	1171	1174	the
B-outcome	1175	1181	ductal
I-outcome	1182	1191	carcinoma
O	1192	1194	in
B-cv-bin-percent	1195	1197	70
I-cv-bin-percent	1197	1198	%
O	1199	1201	of
O	1202	1205	the
O	1206	1211	group
O	1212	1216	with
O	1217	1226	tamoxifen
O	1227	1230	use
O	1230	1231	,
O	1232	1237	while
O	1238	1240	in
O	1241	1252	anastrozole
O	1253	1258	group
O	1259	1262	was
B-iv-bin-percent	1263	1265	90
I-iv-bin-percent	1265	1266	%
O	1266	1267	;
O	1268	1271	the
B-outcome	1272	1282	mastectomy
I-outcome	1283	1288	prior
I-outcome	1289	1291	to
I-outcome	1292	1295	the
I-outcome	1296	1305	tamoxifen
O	1306	1309	was
O	1310	1317	carried
O	1318	1321	out
O	1322	1324	in
B-iv-bin-percent	1325	1327	60
I-iv-bin-percent	1327	1328	%
O	1329	1331	of
O	1332	1335	the
O	1336	1344	patients
O	1345	1348	and
O	1349	1351	in
B-cv-bin-percent	1352	1354	50
I-cv-bin-percent	1354	1355	%
O	1356	1358	of
O	1359	1362	the
O	1363	1368	group
O	1369	1373	with
O	1374	1385	anastrozole
O	1385	1386	.

O	1387	1390	The
O	1391	1401	acceptable
O	1402	1410	response
O	1411	1413	to
O	1414	1417	the
O	1418	1428	processing
O	1429	1431	in
O	1432	1435	the
O	1436	1444	patients
O	1445	1449	with
O	1450	1459	tamoxifen
O	1460	1463	was
B-outcome	1464	1472	complete
O	1473	1475	in
O	1476	1479	the
B-cv-bin-percent	1480	1482	60
I-cv-bin-percent	1482	1483	%
O	1484	1486	of
O	1487	1490	the
O	1491	1496	cases
O	1496	1497	,
O	1498	1501	but
O	1502	1506	with
O	1507	1510	the
O	1511	1514	use
O	1515	1517	of
O	1518	1529	anastrozole
O	1530	1533	was
B-iv-bin-percent	1534	1536	80
I-iv-bin-percent	1536	1537	%
O	1537	1538	;
B-outcome	1539	1547	survival
O	1548	1550	in
O	1551	1554	the
O	1555	1560	group
O	1561	1565	with
O	1566	1577	anastrozole
O	1578	1581	was
O	1582	1584	of
B-iv-bin-percent	1585	1588	100
I-iv-bin-percent	1588	1589	%
O	1590	1592	in
O	1593	1596	two
O	1597	1602	years
O	1603	1605	of
O	1606	1612	follow
O	1613	1615	up
O	1615	1616	,
O	1617	1622	while
O	1623	1625	in
O	1626	1631	women
O	1632	1636	that
O	1637	1645	received
O	1646	1655	tamoxifen
O	1656	1659	the
O	1660	1668	survival
O	1669	1672	was
B-cv-bin-percent	1673	1675	90
I-cv-bin-percent	1675	1676	%
O	1677	1678	(
O	1678	1679	p
O	1679	1680	<
O	1680	1681	0
O	1681	1682	.
O	1682	1685	001
O	1685	1686	)
O	1686	1687	.

O	1688	1691	The
O	1692	1695	use
O	1696	1698	of
O	1699	1710	anastrozole
O	1711	1719	improved
O	1720	1723	the
B-outcome	1724	1732	survival
O	1733	1735	as
O	1736	1740	well
O	1741	1743	as
O	1744	1747	the
B-outcome	1748	1755	quality
I-outcome	1756	1758	of
I-outcome	1759	1763	life
O	1763	1764	,
O	1765	1772	showing
O	1773	1775	no
O	1776	1780	side
O	1781	1788	effects
O	1789	1791	in
O	1792	1796	this
O	1797	1802	group
O	1803	1805	of
O	1806	1814	patients
O	1814	1815	.
